Myeloid cell leukemia-1 （MCL-1）is an anti-apoptotic protein that plays a key role in promoting cell survival in multiple myeloma，acute myeloid leukemia and non-Hodgkin lymphoma. MCL-1 is highly expressed in a variety of hematological malignancies，which is one of the important factors leading to poor prognosis and chemoresistance in patients with hematological malignancies. Therefore，MCL-1 is an important therapeutic target for hematological malignancies. Several MCL-1 inhibitors have entered clinical trials，including S63845，AZD5991，S64315，AMG-176，and AMG-397. The treatment plans used for hematological malignancies include monotherapy with MCL-1 inhibitors，as well as combination therapy with B cell lymphoma 2 inhibitors or immunomodulatory drugs，all indicating that MCL-1 inhibitors may be a breakthrough point for targeted treatment of hematological malignancies.